Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles matching "new medicines"

PolicyCONGRESSMay 1

ISPOR 2026: Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations.

Researchers presented new guidelines on how European Union countries and the United Kingdom decide whether to approve and pay for treatments for rare diseases and children's conditions. These guidelines help governments figure out if new medicines are worth the cost and provide good value for patients. The study looked at how different countries make these decisions and what factors they consider most important.

WHY IT MATTERSIf you have a rare disease or care for a child with one in Europe or the UK, these guidelines directly affect which new treatments your doctor can prescribe and whether your insurance will cover them.
ℹ Good to know
PolicyRSSApr 20

FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development

The FDA announced it has completed its first year of goals to reduce the use of animals in drug testing. The agency launched several new programs to replace animal testing with alternative methods that are often faster and more accurate. This shift means new medicines can be developed and tested in ways that don't require testing on animals.

WHY IT MATTERSFaster, more reliable drug testing methods could accelerate the development and approval of treatments for rare diseases, potentially bringing new therapies to patients years sooner than traditional animal testing timelines allow.
ℹ Good to know
PolicyPUBMEDMar 26

Health Technology Assessment Guidelines and Recommendations Across European Union Countries and the United Kingdom in Rare Disease and Paediatric Populations.

European countries are updating their rules for deciding whether new medicines work well and are worth the cost, especially for rare diseases and children. Because rare diseases affect few people and there's less testing data available, countries are making special adjustments to their evaluation methods. This study looked at how 28 European countries and the UK are handling these evaluations differently.

WHY IT MATTERSIf your country updates its health technology assessment rules, it could affect how quickly new rare disease treatments get approved and whether your insurance will cover them.
ℹ Good to knowrare diseasespediatric diseases

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases